Register a trial

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04451044




Registration number
NCT04451044
Ethics application status
Date submitted
23/06/2020
Date registered
30/06/2020

Titles & IDs
Public title
Distal Evaluation of Functional Performance With Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting
Scientific title
Distal Evaluation of Functional Performance With Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting
Secondary ID [1] 0 0
190103
Universal Trial Number (UTN)
Trial acronym
DEFINE GPS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Coronary Artery Disease 0 0
Ischemic Heart Disease 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Coronary heart disease
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Philips SyncVision system with Philips pressure wires
Treatment: Surgery - standard of care angiographically-guided PCI

Experimental: physiologically-guided arm - Physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy

Active comparator: angiographically-guided arm - Standard of care angiographically-guided PCI for determining the PCI strategy


Treatment: Devices: Philips SyncVision system with Philips pressure wires
Intent to use physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy

Treatment: Surgery: standard of care angiographically-guided PCI
Intent to use PCI standard of care angiographically-guided PCI for determining the PCI strategy
Intervention code [1] 0 0
Treatment: Devices
Intervention code [2] 0 0
Treatment: Surgery
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Major Adverse Cardiac Events (MACE; composite of cardiac death, target vessel MI (TVMI), or ischemia-driven revascularization) or hospitalization for progressive or unstable angina at 2 years
Timepoint [1] 0 0
2 years
Secondary outcome [1] 0 0
Major Adverse Cardiac Events (MACE; composite of cardiac death, target vessel MI (TVMI), or ischemia-driven revascularization) or hospitalization for progressive or unstable angina
Timepoint [1] 0 0
30 days, 1 year
Secondary outcome [2] 0 0
All-cause, cardiac and non-cardiac mortality
Timepoint [2] 0 0
30 days, 1 year and 2 years
Secondary outcome [3] 0 0
All MI, target vessel MI, non-target vessel MI, procedural MI, non-procedural MI
Timepoint [3] 0 0
30 days, 1 year and 2 years
Secondary outcome [4] 0 0
Ischemia-driven revascularization, including all revascularization, TVR, TLR, non-TLR TVR, and non-TVR
Timepoint [4] 0 0
30 days, 1 year and 2 years
Secondary outcome [5] 0 0
Hospitalization for progressive or unstable ischemia
Timepoint [5] 0 0
30 days, 1 year and 2 years
Secondary outcome [6] 0 0
Stent thrombosis (definite, probable and definite/probable)
Timepoint [6] 0 0
30 days, 1 year and 2 years
Secondary outcome [7] 0 0
Angina-related Quality of Life
Timepoint [7] 0 0
30 days, 1 year and 2 years
Secondary outcome [8] 0 0
Resource utilization
Timepoint [8] 0 0
30 days, 1 year and 2 years
Secondary outcome [9] 0 0
Cost effectiveness
Timepoint [9] 0 0
30 days, 1 year and 2 years

Eligibility
Key inclusion criteria
* 1. Adult men and women (local age of consent) who present with stable or unstable angina, or NSTEMI.
* 2. Undergoing cardiac catheterization with planned PCI or possible ad hoc PCI
* 3. Following angiography, PCI is indicated in at least one coronary artery* on the basis of one or more of the following:

1. Presenting with NSTE-ACS (unstable angina with ECG changes or cardiac enzyme-positive NSTEMI) with an identified culprit lesion with DS =50%;
2. One or more angiographic stenoses present with =80% stenosis severity by visual estimation;
3. One or more angiographic stenoses present with =50% to <80% stenosis severity by visual estimation and an abnormal non-invasive stress test in the distribution of the lesion(s) within the past 60 days;
4. One or more angiographic stenoses are present with =50% to <80% stenosis severity by visual estimation and a spot iFR measure =0.89 or FFR=0.80 for borderline iFR..
* 4 Subject is willing to comply with all scheduled visits and tests and has provided informed written consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* 1. STEMI within 30 days
* 2. PCI within the prior 12 months, or any PCI planned after the study procedure (other than planned staged procedures of randomized vessels which are allowed)
* 3. Prior CABG anytime
* 4. Silent ischemia only (i.e. no cardiac symptoms related to coronary artery disease) within the prior 4 weeks
* 5. Documented prior iFR pullback performed in any coronary artery including during the qualifying diagnostic angiogram
* 6. Any vessel with in-stent restenosis (ISR) requiring treatment
* 7. Cardiogenic shock defined as systolic blood pressure <90 mmHg for >20 minutes not responding to fluid resuscitation, or need for inotropic, pressor, or device-based hemodynamic support
* 8. Presence of unstable ventricular arrhythmias
* 9. Heart rate > 110, including uncontrolled atrial fibrillation (AF)
* 10. Decompensated congestive heart failure (NYHA Class IV or Killip Class III or IV)
* 11. Chronic total occlusion (CTO) of a target vessel (exception: a CTO may be present in a non-target vessel if it is supplying non-viable myocardium and there is no intent to open the CTO during the index or later procedure)
* 12. Coronary anatomy not amenable to pressure wire manipulation due to extreme tortuosity or complexity such that it is unlikely that a pressure wire could be passed to the distal third of the three major epicardial coronary arteries
* 13. Any angiographic giant thrombus (i.e., thrombus length > 3x RVD at lesion)
* 14. Any target vessel with < TIMI III flow
* 15. Any target lesion with a reference vessel diameter (RVD) less than 2.25mm except for within the side branch of a bifurcation lesion
* 16. Any non-target lesion with a reference vessel diameter (RVD) greater than 2.00mm that contains an =80% stenosis and is not intended for treatment with PCI (other than a CTO supplying non-viable myocardium - see exclusion #11)
* 17. Known severe aortic or mitral valve stenosis/insufficiency
* 18. Known non-cardiovascular comorbidity resulting in lifespan <24 months
* 19. Known left ventricular ejection fraction =30%
* 20. Estimated creatinine clearance (MDRD formula) <30 mL/min/1.73m2 or on dialysis
* 21. Any cardiac or non-cardiac surgical procedure planned within 12 months after enrollment, or any procedure planned within 6 months after enrollment that would necessitate discontinuation of dual antiplatelet therapy
* 22. Known pregnancy or planning to become pregnant (women of child-bearing potential must have a negative pregnancy test within 1 week of enrollment)
* 23. Participating in another investigational drug or device study that has not reached its primary endpoint
* 24. Any condition such as dementia or substance abuse that may impair the patient's ability to comply with all study procedures, including medication compliance and follow-up visits
* 25. Patient is a member of a vulnerable population who, in the judgment of the investigator, is unable to give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. This may include individuals with mental disability, persons in nursing homes, children, impoverished persons, persons in emergency situations, homeless persons, nomads, refugees, and those permanently incapable of giving informed consent. Vulnerable populations also include university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
NA
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/06/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2028
Actual
Sample size
Target
3212
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Gosford Hospital - Gosford
Recruitment hospital [2] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [3] 0 0
Royal North Shore Hospital - Saint Leonards
Recruitment hospital [4] 0 0
Prince of Wales Hospital - Sydney
Recruitment hospital [5] 0 0
Lake Macquarie Private Hospital - Gateshead
Recruitment postcode(s) [1] 0 0
- Gosford
Recruitment postcode(s) [2] 0 0
- Liverpool
Recruitment postcode(s) [3] 0 0
- Saint Leonards
Recruitment postcode(s) [4] 0 0
- Sydney
Recruitment postcode(s) [5] 0 0
- Gateshead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
District of Columbia
Country [8] 0 0
United States of America
State/province [8] 0 0
Florida
Country [9] 0 0
United States of America
State/province [9] 0 0
Georgia
Country [10] 0 0
United States of America
State/province [10] 0 0
Hawaii
Country [11] 0 0
United States of America
State/province [11] 0 0
Illinois
Country [12] 0 0
United States of America
State/province [12] 0 0
Indiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Kansas
Country [14] 0 0
United States of America
State/province [14] 0 0
Massachusetts
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
Nebraska
Country [18] 0 0
United States of America
State/province [18] 0 0
New Hampshire
Country [19] 0 0
United States of America
State/province [19] 0 0
New York
Country [20] 0 0
United States of America
State/province [20] 0 0
North Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Ohio
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
South Dakota
Country [24] 0 0
United States of America
State/province [24] 0 0
Tennessee
Country [25] 0 0
United States of America
State/province [25] 0 0
Texas
Country [26] 0 0
United States of America
State/province [26] 0 0
Virginia
Country [27] 0 0
United States of America
State/province [27] 0 0
Wisconsin
Country [28] 0 0
Austria
State/province [28] 0 0
Feldkirch
Country [29] 0 0
Canada
State/province [29] 0 0
British Columbia
Country [30] 0 0
Canada
State/province [30] 0 0
Quebec
Country [31] 0 0
Canada
State/province [31] 0 0
Brampton
Country [32] 0 0
Canada
State/province [32] 0 0
Montréal
Country [33] 0 0
Canada
State/province [33] 0 0
Toronto
Country [34] 0 0
Denmark
State/province [34] 0 0
Aarhus
Country [35] 0 0
France
State/province [35] 0 0
Lille
Country [36] 0 0
France
State/province [36] 0 0
Nîmes
Country [37] 0 0
Germany
State/province [37] 0 0
Berlin
Country [38] 0 0
Germany
State/province [38] 0 0
Erlangen
Country [39] 0 0
Germany
State/province [39] 0 0
Essen
Country [40] 0 0
Germany
State/province [40] 0 0
Freiburg
Country [41] 0 0
Israel
State/province [41] 0 0
Hadera
Country [42] 0 0
Israel
State/province [42] 0 0
Tel Aviv
Country [43] 0 0
Italy
State/province [43] 0 0
Florence
Country [44] 0 0
Korea, Republic of
State/province [44] 0 0
Bucheon
Country [45] 0 0
Korea, Republic of
State/province [45] 0 0
Daegu
Country [46] 0 0
Korea, Republic of
State/province [46] 0 0
Seoul
Country [47] 0 0
Mexico
State/province [47] 0 0
Querétaro
Country [48] 0 0
Netherlands
State/province [48] 0 0
Dordrecht
Country [49] 0 0
Netherlands
State/province [49] 0 0
Enschede
Country [50] 0 0
Netherlands
State/province [50] 0 0
Leeuwarden
Country [51] 0 0
Netherlands
State/province [51] 0 0
Nieuwegein
Country [52] 0 0
Netherlands
State/province [52] 0 0
Nijmegen
Country [53] 0 0
Poland
State/province [53] 0 0
Warsaw
Country [54] 0 0
Portugal
State/province [54] 0 0
Amadora
Country [55] 0 0
Spain
State/province [55] 0 0
Córdoba
Country [56] 0 0
Spain
State/province [56] 0 0
León
Country [57] 0 0
Spain
State/province [57] 0 0
Madrid
Country [58] 0 0
Spain
State/province [58] 0 0
Santander
Country [59] 0 0
Sweden
State/province [59] 0 0
Lund
Country [60] 0 0
Sweden
State/province [60] 0 0
Örebro
Country [61] 0 0
Switzerland
State/province [61] 0 0
Geneva
Country [62] 0 0
United Kingdom
State/province [62] 0 0
Hampshire
Country [63] 0 0
United Kingdom
State/province [63] 0 0
Wales
Country [64] 0 0
United Kingdom
State/province [64] 0 0
Bournemouth
Country [65] 0 0
United Kingdom
State/province [65] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Philips Clinical & Medical Affairs Global
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Allen Jeremias, MD MSC FACC FSCAI
Address 0 0
Saint Francis Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT04451044